

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Vincent VIEILLARD
Patrice DEBRE

Serial No.: 10/588,633

Filed: August 4, 2006

For: POLYPEPTIDE DERIVED FROM GP41,
A VACCINE COMPOSITION
COMPRISING SAID POLYPEPTIDE,
AND USES FOR TREATING AN
INFECTION BY AN HIV VIRUS IN AN
INDIVIDUAL

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: CHEP:019US

Confirmation No.: 5091

CERTIFICATE OF ELECTRONIC TRANSMISSION
37 C.F.R. § 1.8

I hereby certify that this correspondence is being
electronically filed with the United States Patent and
Trademark Office via EFS-Web on the date below.

February 19, 2007

Date

Mark P. Wilson

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CHEP:019US.

This application may be related by inventorship and subject matter to co-pending U.S. application number 10/544,884, filed May 17, 2006.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 19, 2007

Form PTO-1449 (modified)		Atty. Docket No.: CHEP:019US	Serial No.: 10/588,633
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Vincent VIEILLARD Patrice DEBRE	
		Filing Date: August 4, 2006	Group: Unknown
U.S. Patent Documents <i>See Page I</i>	Foreign Patent Documents <i>See Page I</i>	Other Art <i>See Page I</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	CA 2431881	07/11/02	Canada	English
	B2	WO 02/053587	07/11/02	WIPO	Abstract
	B3	WO 02/08287	01/31/02	WIPO	English
	B4	WO 98/20036	05/14/98	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Chen <i>et al.</i> , "Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41," <i>AIDS Research and Human Retroviruses</i> , 16(18):2037-2041, 2000.
	C2	Emerling <i>et al.</i> , "MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia," <i>Oncogene</i> , 21:4849-4854, 2002.
	C3	Mwaengo and Novembre, "Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections," <i>Journal of Virology</i> , 72(11):8976-8987, 1998.
	C4	Ryu <i>et al.</i> , "Development of an in vitro assay system for screening of gp41 inhibitory compounds," <i>Mol. Cells</i> , 8(6):717-723, 1998.
	C5	Vieillard <i>et al.</i> , "NK cytotoxicity against CD4+ T cells during HIV-1 expression of an NKp44 ligand," <i>Proc. Natl. Acad. Sci. USA</i> , 102:10981-10986, 2005.

25741581.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.